ArticleVeterinary world2025
Immunoinformatic development of a multiepitope messenger RNA vaccine targeting lipoate protein ligase and dihydrolipoamide dehydrogenase proteins of
Article in Veterinary world, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: Materials and Methods: Two conserved surface-exposed proteins - lipoate protein ligase (LplA) and dihydrolipoamide dehydrogenase (PdhD) - were selected as vaccine targets. T- and B-cell epitopes were predicted using Immune Epitope Database and evaluated for antigenicity, allergenicity, toxicity, and conservancy. Selected epitopes were linked using specific amino acid linkers and combined with a resuscitation-promoting factor E (RpfE) adjuvant and untranslated regions (hemoglobin subunit beta and rabbit beta-globin) to improve translation and stability. The vaccine construct was modeled and validated through physicochemical profiling, secondary and tertiary structure prediction, molecular-docking with bovine toll-like receptors 4 (TLR4), and codon optimization. Molecular dynamics simulations were conducted to assess the stability of the vaccine-receptor complex. Results: The modeled vaccine construct contained five cytotoxic T lymphocyte, six helper T lymphocyte, and five B-cell epitopes. The construct was predicted to be highly antigenic (score: 0.835), non-allergenic, and non-toxic. Structural validation showed 93.5% of residues in favored regions of the Ramachandran plot and a Z-score of -10.6. Docking simulations revealed strong binding affinity to bovine TLR4, supported by robust molecular dynamics simulation outcomes, including high stability, low eigenvalues, and favorable covariance patterns. Codon optimization yielded a guanine-cytosine content of 59.8% and a codon adaptation index of 0.87, indicating efficient expression in cattle. The predicted mRNA structure exhibited good thermodynamic stability (minimum free energy: -321.42 kcal/mol). Conclusion: This study presents a computationally designed mRNA vaccine candidate against
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.